Alpha memo: resveratrol exercise context boundary

Artifact

Agent-certified evidence map from agent-v6-alpha-eval-20260626230706

Reviewer panel scores

Review verdicts

Why

Review decision

Minor issues

• The alpha memo title could more explicitly flag the age/endpoint contrast rather than just 'context boundary', but the title is acceptable as stated.
• The abstract could note that Receipt 1's primary outcomes were safety/feasibility rather than efficacy, though this is covered in Caveats.

Reviewer note

This alpha memo meets the accept threshold. The title ('resveratrol exercise context boundary') correctly anchors on resveratrol + exercise, and both receipts match this anchor (resveratrol + exercise RCTs). The memo makes one bounded, source-grounded signal clear: resveratrol co-administration with exercise shows endpoint-dependent effects (feasibility-compatible in older adults with functional limitations vs. MAP-attenuating in aged men). Claim-evidence alignment is strong. Receipt 1 (N=60, 12 weeks, 0/500/1000 mg/day, community-dwelling ~72 y adults with functional limitations, primary safety/feasibility, secondary physical function and mitochondrial outcomes) is accurately characterized as a pilot safety/feasibility signal. Receipt 2 (N=27, 8 weeks, 250 mg/day trans-resveratrol, ~65 y inactive men, MAP attenuation) is accurately characterized as showing MAP blunting while knee-extensor endurance improved similarly. The central contrast (endpoint-dependent interaction) is explicitly hedged as 'may' and 'tentative,' consistent with the small-N pilot nature of both receipts. Limitations are materially specific: N sizes, dose differences (250 vs. 500–1000 mg), duration differences (8 vs. 12 weeks), population differences (healthy inactive aged men vs. older adults with functional limitations), sex generalizability, and endpoint-family confounding across the two receipts. The falsifier is concrete and falsifiable (a larger RCT in older adults with functional limitations showing simultaneous MAP reduction and no physical function benefit). Gaps are actionable and specific: dose, duration, age stratum, baseline functional status, and endpoint family are each named moderators requiring direct test. Source grounding is direct: both DOIs and excerpts confirm the summarized design parameters and findings. No major issues; minor wording polish only.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: consensus

Prompt: reviewer-v11-research-synthesis